Worldwide revenue for the third quarter of 2015 totaled $74.1 million,
representing a decrease of 2% as-reported compared to $75.7 million
reported for the third quarter of 2014. Constant currency revenue
increased by 1% versus the prior year period.

The Company’s third quarter 2015 net income totaled $5.4 million or
$0.18 per diluted share, an improvement of $6.3 million compared to a
net loss of $900,000 or $(0.05) per diluted share in the third quarter
of 2014. Third quarter net income results reflect gross margin expansion
driven by the continued strong performance of DEFINITY®
along with the effect of customer-specific changes within the Company’s
nuclear medicine portfolio that occurred earlier this year, accompanied
by reduced interest expense resulting from the Company’s recent debt
refinancing.

The Company’s third quarter 2015 Adjusted EBITDA, as defined in the GAAP
to non-GAAP reconciliation provided later in this release, increased to
$19.4 million, or 26.2% of reported revenue, compared to $19.1 million,
or 25.2% of reported revenue, in the third quarter of 2014.

Mary Anne Heino, President and CEO commented, “Our third quarter
performance reflects the continued successful execution of our business
strategy. During the third quarter we again experienced a strong sales
performance for DEFINITY, driven by the continued growth of the U.S.
ultrasound contrast market. DEFINITY sales increased by 20% in constant
currency while growing sequentially for the thirteenth consecutive
quarter. At the same time, our nuclear medicine portfolio continued to
exhibit the profile of improved customer mix and profitability that we
established earlier this year.”

Ms. Heino continued, “Overall, DEFINITY’s growing contribution combined
with continued gross margin improvement and operating expense management
has significantly expanded our operating and Adjusted EBITDA margins
since last year, driving those margins to 18% and 26%, respectively, of
reported revenue for the third quarter. Altogether, we are very pleased
with our third quarter results and look forward to the remainder of this
year and beyond, as we continue to focus on strengthening our operating
model and enhancing our ability to meet and exceed the needs of our
customers.”

Outlook

The Company anticipates worldwide revenue for full-year 2015 of
approximately $292 million to $294 million, representing a constant
currency change over last year of approximately negative (1)% to 0%,
compared to previous guidance of $293 million to $297 million. This
range assumes a negative full-year impact from currency of approximately
$7 million, or 2%, compared to 2014.

The Company continues to anticipate full-year 2015 Adjusted EBITDA, as
described in the GAAP to non-GAAP reconciliation provided later in this
release, of $72 million to $75 million, representing approximately 25%
to 26% of reported revenue.

The Company’s revenue and Adjusted EBITDA targets exclude the effect of
possible future acquisitions or divestitures, other material future
business developments and the adjustments of earnings as-reported to
as-adjusted that are set forth in the GAAP to non-GAAP reconciliations
provided later in this release.

The Company’s guidance for worldwide revenue and Adjusted EBITDA are
forward-looking statements. They are subject to various risks and
uncertainties that could cause the Company’s actual results to differ
materially from the anticipated targets. The anticipated targets are not
predictions of the Company’s actual performance. See the cautionary
information about forward-looking statements in the “Safe-Harbor
Statement” section of this press release.

Internet Posting of Information

The Company routinely posts information that may be important to
investors in the “Investor Relations” section of its website at www.lantheus.com.
The Company encourages investors and potential investors to consult its
website regularly for important information about the Company.

Conference Call and Webcast

As previously announced, the Company will host a conference call
starting at 4:30 p.m. (Eastern Time) today. To access the live
conference call via telephone, please dial 1-866-498-8390 (U.S. callers)
or 1-678-509-7599 (international callers) and provide passcode 57541328.
A live audio webcast of the call also will be available on the homepage
of the Company’s website at www.lantheus.com.

A replay of the telephone conference call and audio webcast will be
available from approximately 8:30 p.m. ET on November 4, 2015 through
midnight on November 18, 2015. To access a replay of the conference
call, dial 1-855-859-2056 (U.S. callers) or 1-404-537-3406
(international callers), and provide passcode 57541328. A replay of this
conference call will also be available in the Investor Relations section
of our website located at www.lantheus.com.

The conference call will include a discussion of non-GAAP financial
measures. Reference is made to the most directly comparable GAAP
financial measures, the reconciliation of the differences between the
two financial measures, and the other information included in this press
release, our Form 8-K filed with the SEC today, or otherwise available
in the Investor Relations section of our website located at www.lantheus.com.

The conference call may include forward-looking statements. See the
cautionary information about forward-looking statements in the
safe-harbor section of this press release.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.

Lantheus Holdings, Inc. is the parent company of LMI, which is a global
leader in developing, manufacturing, selling and distributing innovative
diagnostic imaging agents and products. LMI provides a broad portfolio
of products, which are primarily used for the diagnosis of
cardiovascular diseases. LMI’s key products include the echocardiography
contrast agent DEFINITY® Vial for (Perflutren Lipid
Microsphere) Injectable Suspension; TechneLite® (Technetium
Tc99m Generator), a technetium-based generator that provides the
essential medical isotope used in nuclear medicine procedures; and Xenon
(Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to
evaluate pulmonary function and for imaging the lungs. The Company is
headquartered in North Billerica, Massachusetts, and has offices in
Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as net sales
excluding the impact of foreign currency; operating income, as adjusted;
net income, as adjusted; Adjusted EBITDA; net income, as adjusted, per
diluted share; Adjusted EBITDA per diluted share; and free cash flow.
The Company’s management believes that the presentation of these
measures provides useful information to investors. These measures may
assist investors in evaluating the Company’s operations, period over
period. The measures may exclude such items which may be highly
variable, difficult to predict and of a size that could have substantial
impact on the Company’s reported results of operations for a period.
Management uses these and other non-GAAP measures internally for
evaluation of the performance of the business, including the allocation
of resources and the evaluation of results relative to employee
performance compensation targets. Investors should consider these
non-GAAP measures only as a supplement to, not as a substitute for or as
superior to, measures of financial performance prepared in accordance
with GAAP.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains “forward-looking statements” as defined
under U.S. federal securities laws, including statements about our 2015
outlook. These statements reflect management’s current knowledge,
assumptions, beliefs, estimates and expectations and express
management’s current view of future performance, results and trends.Forward-looking
statements may be identified by their use of terms such as anticipate,
believe, confident, could, estimate, expect, intend, may, plan, predict,
project, target, will and other similar terms.Such
forward-looking statements are subject to risks and uncertainties that
could cause actual results to materially differ from those described in
the forward-looking statements.Readers are cautioned not to
place undue reliance on the forward-looking statements contained herein,
which speak only as of the date hereof. The Company undertakes no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future developments or otherwise, except as
may be required by law.Risks and uncertainties that could cause
our actual results to materially differ from those described in the
forward-looking statements are discussed in our filings with the
Securities and Exchange Commission (including those described in the
Risk Factors section of our prospectus dated June 24, 2015 and filed
with the SEC on June 26, 2015, and as may be further set forth or
supplemented in our Annual Reports on Form 10-K and our Quarterly
Reports on Form 10-Q).

Lantheus Holdings, Inc. and subsidiaries

Condensed Consolidated Statements of Operations

(in thousands, except per share data – unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2015

2014

2015

2014

Revenues

$

74,123

$

75,682

$

222,260

$

224,631

Cost of goods sold

40,418

44,044

120,119

131,873

Gross profit

33,705

31,638

102,141

92,758

Operating expenses

Sales and marketing expenses

8,633

8,327

26,934

27,227

General and administrative expenses

9,206

11,041

33,773

28,883

Research and development expenses

2,458

3,049

11,292

8,958

Total operating expenses

20,297

22,417

71,999

65,068

Operating income

13,408

9,221

30,142

27,690

Interest expense, net

(7,100

)

(10,585

)

(31,599

)

(31,704

)

Loss on extinguishment of debt

—

—

(15,528

)

—

Other income (expense), net

(183

)

441

234

(148

)

Income (loss) before income taxes

6,125

(923

)

(16,751

)

(4,162

)

Provision (benefit) for income taxes

739

(56

)

1,911

(374

)

Net income (loss)

$

5,386

$

(867

)

$

(18,662

)

$

(3,788

)

Net income (loss) per common share

Basic and diluted

$

0.18

$

(0.05

)

$

(0.83

)

$

(0.21

)

Common shares

Basic

30,359,516

18,080,968

22,443,257

18,080,496

Diluted

30,761,771

18,080,968

22,443,257

18,080,496

Lantheus Holdings, Inc. and subsidiaries

Consolidated Revenue Analysis

(dollars in thousands – unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2015

2014

% change

2015

2014

% change

U.S.

DEFINITY

28,323

23,764

19.2

%

81,333

68,768

18.3

%

TechneLite

14,557

20,879

(30.3

)%

47,367

61,602

(23.1

)%

Xenon

12,713

8,914

42.6

%

37,937

27,519

37.9

%

Other

3,619

5,872

(38.4

)%

11,620

16,919

(31.3

)%

Total U.S.

$

59,212

$

59,429

(0.4

)%

$

178,257

$

174,808

2.0

%

International

DEFINITY

560

497

12.7

%

1,644

1,368

20.2

%

TechneLite

2,666

2,733

(2.5

)%

8,078

8,576

(5.8

)%

Xenon

10

2

400.0

%

28

6

366.7

%

Other

11,675

13,021

(10.3

)%

34,253

39,873

(14.1

)%

Total International

$

14,911

$

16,253

(8.3

)%

$

44,003

$

49,823

(11.7

)%

Worldwide

DEFINITY

28,883

24,261

19.1

%

82,977

70,136

18.3

%

TechneLite

17,223

23,612

(27.1

)%

55,445

70,178

(21.0

)%

Xenon

12,723

8,916

42.7

%

37,965

27,525

37.9

%

Other

15,294

18,893

(19.0

)%

45,873

56,792

(19.2

)%

Total Revenues

$

74,123

$

75,682

(2.1

)%

$

222,260

$

224,631

(1.1

)%

Lantheus Holdings, Inc. and subsidiaries

Supplemental Revenue Information

(unaudited)

September 30, 2015 Quarter to Date Sales Growth/(Decline)

Domestic AsReported

Int’l ConstantCurrency

Int’l AsReported

Total ConstantCurrency

Total AsReported

Products

DEFINITY

19%

37%

13%

20%

19%

TechneLite

(30)%

13%

(2)%

(25)%

(27)%

Xenon

43%

450%

400%

43%

43%

Other

(38)%

3%

(10)%

(10)%

(19)%

Total Revenues

0%

6%

(8)%

1%

(2)%

September 30, 2015 Year to Date Sales Growth/(Decline)

Domestic AsReported

Int’l ConstantCurrency

Int’l AsReported

Total ConstantCurrency

Total AsReported

Products

DEFINITY

18%

39%

20%

19%

18%

TechneLite

(23)%

5%

(6)%

(20)%

(21)%

Xenon

38%

433%

367%

38%

38%

Other

(31)%

(4)%

(14)%

(12)%

(19)%

Total Revenues

2%

(1)%

(12)%

1%

(1)%

Lantheus Holdings, Inc. and subsidiaries

Reconciliation of Revenues to Revenues Excluding the Impact of
Foreign Currency